Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $897
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has maintained an 'Overweight' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) but lowered the price target from $927 to $897.
July 11, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Regeneron Pharmaceuticals' price target has been lowered by Morgan Stanley from $927 to $897, though the 'Overweight' rating is maintained.
The news is directly about Regeneron Pharmaceuticals and is likely to influence investor sentiment. The lowering of the price target might be seen as a negative signal, but the maintenance of the 'Overweight' rating indicates that the analyst still sees potential in the stock. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100